🔴 Moleculin Biotech is trading 6.1% down in pre-market with no clear catalyst established

Moleculin Biotech is trading 6.14% down at $5.81 pre-market; no clear catalyst is established.

• The 1-for-20 reverse split took effect October 20, when split-adjusted trading began.
• The CEO cited completed Part A enrollment and encouraging interim MIRACLE results; full data are expected Q1 2027. Reports do not directly link these to the October 21 pre-market decline.
• Prior close: $6.19 after a sharp split-adjusted move; history reflects a major share-count adjustment. Broader biotech strength is not an obvious explanation.